Introduction
There are several drugs which can be used to obtain remission of acute lymphoblastic leukaemia (A.L.L.). Since the combination of prednisolone and vincristine is successful in 85-90% of cases (Aur et al., 1971; Medical Research Council, 1971 , 1973 Holland and Glidewell, 1972) it should seldom be necessary to add another agent, but rhe addition of colaspase (L-asparaginase) may be valuable in hastening the onset and increasing the incidence of remission (Oettgen et al., 1970) . Thoug-h complications not uncommonly result from its use (Land et al., 1970 ) colaspase used in short courses which do not allow sensitization to occur is relatively non-toxic.
By comparing the induction phase of treatment in three trials, only one of which included colaspase, we have assessed the benefits and hazards of combining colaspase with prednisolone and vincristine in the initial treatment of A.L.L.
Patients and Methods
The patients studied were in three consecutive trials undertaken for the Medical Research Council by its Leukaemia Commnittee and Working Party on Leukaemia in Childhood between January 1969 and April 1973. The three trials were Concord (January 1969 to August 1970) (Medical Research Council, 1971) April 1973) . In each trial the therapy was identical for the first six weeks apart from the addition of colaspase in the UKALL II trial. Prednisolone 40 mg/mi was given daily by mouth for five weeks, tailing off during the sixth week; vincristine 1-5 mg/m2 was given intravenously on days 1, 8 and 15; and from day 21 mercaptopurine 70 mg/rn2 was given daily by mouth. Allopurinol, when used, was discontinued before mercaptopurine was started. In the UKALL II trial only intravenous or intramuscular colaspase 10,000 U/m2 was given on days 1, 3, 5, and 8. Treatment after the sixth week varied in many ways between the three trials.
The patients studied had all been entered into the trials at participating centres (A.H.) , and the Royal Hospital for Sick Children, Edinburgh (R.H.S.C.), on whom routine blood counts were performed daily or on altemative days.
Neutrophil and platelet counts were analysed in three ways: (1) absolute counts on days 0, 7+1, 14+1, and 21+1; (2) number of day-s from the start of treatment to the lowest recorded neutrophil and platelet counts and the absolute counts at the nadir (RM.H., A.H., and R.H.S.C. only; this analysis could not be done on patients at G.O.S., many of whom were treated as outpatients); and (3) number of days from the start of treatment to recovery to 100,000 platelets and 1,000 and 1,500 neutrophils per mm3.
Means and confidence limits were calculated by taling the logarithms of the actual values of the individual observationis and computing the means and standard errors of these transformed values. The figure shown in tables I and II are those obtained after taking antilogarithms of the values thus derived. This was done in an attempt to compensate for the skewness in the distributions of seme of the observed data. Significance testing was performed on the ranked data using the Wilcoxon rank sum test.
Results
Peripheral Blood.-The mean neutrophil count was significantly lower on day 7 in the UKALL II trial than in the UKALL I trial; on day 14 the difference was less but still significant, while there was no significant difference on days 0 and 21 (table I). In the UKALL I trial 4-9 days elapsed before the lowest count was reached, whereas in the UKALL II trial the nadir was not reached until 8-6 days had elapsed. The mean neutrophil count at the nadir was also lower in the UKALL II trial but this was not statistically significant.
There was a significant delay in recovery to 1,000 neutrophils/ mm3 in the UKALL II trial as compared with the UKALL I trial, but a somewhat faster subsequent rise from 1,000 to 1,500 neutrophils/mm' (table II) . No significant differences were found between the platelet counts until day 14, when the mean count was significantly lower in the UKALL II trial (table I). The delay of nearly three days in recovery of platelets to 100,000/nnnm in the UKALL II trial, compared with the UKALL I trial, was similar to that of the recovery of the neutrophil count to 1,000/mm3, though the difference did not reach statistical significance (table II) .
Infections.-Life-threatening infections were noticeably more commn in the UKALL II trial in the first six weeks and the death rate from all causes was significantly increased (P < 0-02) ( Our evidence shows that the addition of colaspase during the first week of the remission induction regimen of vincristine and prednisolone causes a significantly increased suppression of both normal and leukaemic cells in the bone marrow, as shown by the increased blast-cell regression and lower blood neutrophil and platelet counts. The induced neutropenia resulted in an increased liability to serious and fatal infections to which the immunosuppressive effect of colaspase (Maral et al., 1970) , the alteration of neutrophil function by asparagine depletion (Strauss et al., 1970; Skeel et al., 1971) , or an effect of colaspase on the gut mucosa might also have contributed. The clinical importance of the added period of thrombocytopenia is difficult to assess, since bleeding was largely prevented by platelet transfusion.
Colaspase could cause marrow depression either directly or by potentiating the myelotoxicity of vincristine. A potentiating effect might be mediated by the liver, since the hepatotoxicity of colaspase (Land et al., 1970; Pratt and Johnson, 1971) Notwithstanding its observed toxicity, colaspase significantly increased the rate of blast-cell regression in the UKALL II trial. It is possible that this initial reduction of leukaemic cells might lead to an increased duration of remission (Jones and Holland, 1973) , but this could not be tested in these trials because of the differences in subsequent therapy. An increased death rate during remission induction, however, is not an acceptable price to pay for this theoretical advantage. It is probable that a siimilar long-term effect could be obtained by giving colaspase at a later phase in treatrment. It is therefore recommended that colaspase should not be given during the induction phase of treatment in A.L.L. until there is evidence of marrow regeneration or until it becomes clear that other agents are failing to induce remission. Introduction Australia antigen, now referred to as hepatitis B antigen (HBAg) in view of its association with hepatitis B infection provides a reliable serological marker of an agent which causes this type of infection (World Health Organization, 1973) .
In Great Britain the reported prevalence of HBAg in patients admitted to hospital with hepatitis has varied between 4% (Ross
